ArticleBiotechnology and bioengineering2026
Engineered Chondrocalcin From Pichia pastoris: A Dual-Functional Biomaterial for Cartilage Regeneration and Rheumatoid Arthritis Modulation.
Article in Biotechnology and bioengineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hydrogels as Local Structural-Protective Platforms in Rheumatoid Arthritis: An Evidence-Graded Review Across the Synovium-Cartilage-Bone Axis.Gels (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Chondrocalcin (CCN), the C-terminal propeptide of type II procollagen and a key regulatory peptide in collagen assembly, is abundantly expressed in cartilage and implicated in bone-cartilage interface disorders. We engineered a Pichia pastoris strain via genetic modification to produce recombinant chondrocalcin (rCCN), which was isolated, purified, and characterized. Functional assays revealed that rCCN promotes human bone marrow mesenchymal stem cell (hBMSC) differentiation into chondrocytes. Mechanistically, rCCN at 0.3 mg/mL promoted hBMSC chondrogenesis via SOX9/COLII/aggrecan upregulation (2.84-, 7.94-, 9.13-fold) while suppressing fibrotic COL I. In rheumatoid arthritis synoviocytes (HFLS-RA), rCCN reprogrammed the inflammatory microenvironment via the upregulation of COLII/IL-4/TGF-β1 upregulating (0.69-, 4.01-, 1.18-fold), and the downregulating TNF-α, IL-1β, and IL-6. These findings highlight rCCN's dual therapeutic potential as a biomaterial for cartilage repair and inflammatory modulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.